Once-daily vs twice-daily tacrolimus for de novo living kidney transplantation patients including ABO/HLA compatible and incompatible: A randomized trial

2018 ◽  
Vol 32 (12) ◽  
pp. e13423
Author(s):  
Masayoshi Okumi ◽  
Kohei Unagami ◽  
Miyuki Furusawa ◽  
Yoichi Kakuta ◽  
Junpei IIzuka ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Randomized Trial ◽  
De Novo ◽  
Once Daily

Sirolimus vs cyclosporine after induction with basiliximab does not promote regulatory T cell expansion in de novo kidney transplantation: Results from a single-center randomized trial

2015 ◽  
Vol 33 (2) ◽  
pp. 117-124 ◽  
Author(s):  
Carmelo Libetta ◽  
Pasquale Esposito ◽  
Marilena Gregorini ◽  
Elisa Margiotta ◽  
Claudia Martinelli ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
T Cell ◽  
Randomized Trial ◽  
Regulatory T Cell ◽  
Cell Expansion ◽  
De Novo ◽  
Single Center ◽  
T Cell Expansion

Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation

2018 ◽  
Vol 32 (8) ◽  
pp. e13311 ◽  
Author(s):  
Petra Glander ◽  
Johannes Waiser ◽  
Silke Kasbohm ◽  
Frank Friedersdorff ◽  
Robert Peters ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
De Novo ◽  
Once Daily

Pharmacogenetic-based strategy using de novo tacrolimus once daily after kidney transplantation: prospective pilot study

2016 ◽  
Vol 17 (9) ◽  
pp. 1019-1027 ◽  
Author(s):  
Martine De Meyer ◽  
Vincent Haufroid ◽  
Nada Kanaan ◽  
Tom Darius ◽  
Antoine Buemi ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Pilot Study ◽  
De Novo ◽  
Once Daily ◽  
Prospective Pilot Study
Sign in / Sign up

Export Citation Format

Share Document